AI Terminal
Substrate Artificial Inteligence S.A.
Legal Proceedings Report • Oct 7, 2024
6111_rns_2024-10-07_cb14abe9-0f5d-41e6-a563-595a72d50700.html
Legal Proceedings Report
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2428H
Substrate Artificial Inteligence,SA
07 October 2024
7 October 2024
SUBSTRATE ARTIFICIAL INTELIGENCE SOCIEDAD ANONIMA
("Substrate AI" or the "Company")
COMPLETION OF DELIVERY ORDER UNDER AGREEMENT WITH SESPA BY DIAGXIMAG
In April 2024, t he Health Service of the Principality of Asturias (SESPA) awarded Diagximag, a subsidiary company of Cuarta División (4D) Médica, which is in turn a subsidiary of the Company, a contract valued at €1,400,000 for the provision of 54 state-of-the-art ultrasound machines for Asturian public health.
Substrate AI (AQUIS: SAI/SAI.B) is pleased to announce that it has successfully completed the delivery of these ultrasound machines.
The Directors of Substrate AI accept responsibility for this announcement.
| Substrate AI | |
| Lorenzo Serratosa Chairman |
[email protected] |
| First Sentinel Corporate Finance Corporate Advisors |
|
| Brian Stockbridge | +44 (0) 7858 888 007 |
About Substrate AI: Substrate AI is an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, or health. All of them sell products and services built on the bio-inspired reinforced learning technology developed and patented by Substrate AI.
This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXFLFIRISLDIIS